The variant surface antigen VAR2CSA is a pregnancy malaria vaccine candidate, but its size and polymorphism are obstacles to development. We expressed 3D7-type VAR2CSA domains in Escherichia coli as insoluble His-tagged proteins (Duffy binding-like [DBL] domains DBL1, DBL3, DBL4, and DBL5) that were denatured and refolded or as soluble glutathione Stransferase-tagged protein (DBL6). Anti-DBL5 antiserum cross-reacted with surface proteins of chondroitin sulfate A (CSA)-binding laboratory strains (3D7-CSA and FCR3-CSA) and a clinical pregnancy malaria isolate, whereas anti-DBL6 antiserum reacted only to 3D7 surface protein. This is the first report that E. coli-expressed VAR2CSA domains induce antibody to native VAR2CSA.
Placental malaria (PM) is an important cause of morbidity and mortality in sub-Saharan Africa; it causes ϳ20,000 maternal deaths each year and likely contributes to the deaths of 100,000 -200,000 infants [1] . PM results when Plasmodium falciparuminfected erythrocytes (PEs) bind to chondroitin sulfate A (CSA) to sequester in the placenta [2, 3] . CSA-binding PEs are common in samples collected from pregnant donors but not in those from nonpregnant donors. Women become resistant to PM during successive pregnancies as they acquire antibody that blocks PE binding to CSA [4] .
Parasite adhesion may involve the P. falciparum erythrocyte membrane protein 1 (PfEMP1) family, a family of variant surface antigens encoded by ϳ60 var genes in each haploid genome. Transcription and PE surface expression of PfEMP1 VAR2CSA are higher in placental parasites and laboratory parasites selected to bind CSA [5, 6] . Women in malaria-endemic regions develop protection as they acquire antibody to VAR2CSA during successive pregnancies [6 -8] , making VAR2CSA a leading vaccine candidate antigen. Identifying VAR2CSA immunogens that elicit functional cross-reactive antibody is critical to the development of a PM vaccine.
The gene var2csa encodes a protein of 355 kDa with 6 extracellular Duffy binding-like (DBL) domains folded with multiple disulfide bonds [9] . Antisera against baculovirus-expressed but not Escherichia coli-expressed VAR2CSA domains recognize native protein [7] , presumably because of differences in protein folding. To obtain adequate yield in baculovirus, VAR2CSA constructs were engineered to conform to Trichoplusia ni codon usage.
E. coli has advantages over eukaryotic systems for expression of P. falciparum immunogens. High yields are often attainable at low cost using native codons, and E. coli proteins are not N-glycosylated, similar to native malarial proteins [10] . In the present study, we evaluated VAR2CSA domains expressed in E. coli and refolded, as immunogens that elicit antibody to homologous and heterologous native protein.
Methods. Each VAR2CSA domain cDNA was amplified by polymerase chain reaction (PCR) from strain 3D7 P. falciparum genomic DNA, cloned, and verified by sequencing. The amino acid boundaries were as follows: DBL1, 1-449; DBL3, 1193-1519; DBL4, 1569 -1881; DBL5, 1981-2336; and DBL6, 2325-2587. Domains DBL1 through DBL5 were cloned into pET28b to express N-terminal His-tagged proteins, and DBL6 was cloned into pGEX to express N-terminal glutathione S-transferase (GST)-tagged protein. Domain DBL2 failed to yield protein product and was not further evaluated.
E. coli Rosetta 2(DE3)pLysS Singles competent cells (Novagen) were transformed with each construct, induced for protein expression, and then lysed with BugBuster lysis buffer (Novagen). All His-tagged proteins remained in the insoluble fraction, but the GST-tagged DBL6 domain was soluble. His-tagged proteins were purified using nickel-affinity chromatography in 6 mol/L urea (Qiagen), and GST-tagged protein was purified using glutathione resin (Amersham).
His-tagged proteins were reduced and further purified using reverse-phase high-performance liquid chromatography (RP-HPLC; HiPore RP-304 column; BioRad) in an acetonitrile gradient (1 mL/min, 5%-60% in 60 min). These proteins were lyophilized; dissolved in PBS containing 6 mol/L urea, 5 mmol/L reduced glutathione, and 1 mmol/L oxidized glutathione; and then dialyzed overnight against the same buffer without urea. Little or no precipitation of protein occurred during dialysis, and all domains (except DBL4-His) remained soluble after this treatment. DBL4-His was refolded after HPLC by fast buffer exchange using a gel-filtration column equilibrated in PBS containing 5 mmol/L reduced glutathione, 1 mmol/L oxidized glutathione, and 50 mmol/L Tris-hydrogen chloride (pH 9). To prepare unfolded DBL5-His, nickel-purified reduced protein was treated for 1 h at 37°C with iodoacetamide and then purified by RP-HPLC. After purification, this protein (termed DBL5-IAM) was soluble in water or PBS and demonstrated reduced mobility in sodium dodecyl sulfate gel electrophoresis (data not shown).
For parasite culture, clinical isolate 0711 was isolated from the peripheral blood of a pregnant Tanzanian woman [11] and adapted to in vitro culture. The binding phenotype of isolate 0711 and other parasites was assessed by routine methods, as described elsewhere [11] . At the time of collection, 0711 adhered exclusively to CSA [11] . After 3 cycles of multiplication, 0711 adhered predominantly to CSA and maintained this pattern of binding over 4 months in culture. Laboratory isolates FCR3 and 3D7 were panned on immobilized CSA, as described elsewhere [5] , to develop CSA-binding forms (FCR3-CSA and 3D7-CSA), which have been shown to react specifically to immune serum from African multigravidae but not with immune serum from male subjects and have been confirmed to express var2csa transcript by quantitative reverse-transcription PCR using published gene-specific primers and conditions [5, 12] . Trophozoite-stage parasites were used for all seroreactivity assays. Ethical clearance was obtained from the institutional review boards of the Seattle Biomedical Research Institute (SBRI) and the National Medical Research Coordinating Committee in Tanzania.
Rabbits were immunized via inoculation with 100 g of antigen (His-tagged DBL3, DBL4, and DBL5 and GST-tagged DBL6) in complete Freund's adjuvant and 4 boosts with the same amount of antigen in incomplete Freund's adjuvant (at Antibodies Inc.). Mice (3-4 per antigen) were immunized via 4 inoculations with 10 g of antigen (His-tagged DBL1, DBL5, and DBL5-IAM) per injection in TiterMax adjuvant (TiterMax).
Rabbit and mouse antisera were tested by ELISA against the proteins that had been used for immunization. Immunizations were performed with the approval of SBRI's Institutional Animal Care and Use Committee.
Antisera raised against VAR2CSA domains were assessed against live PEs by flow cytometry (FC) and indirect fluorescence assay (IFA). PEs were incubated with immune or preimmune serum (1:25 for FC and 1:10 for IFA), followed by fluorescein-labeled secondary anti-species IgG (Jackson ImmunoResearch Laboratories) diluted 1:100 for FC and 1:40 for IFA. To distinguish PEs from uninfected erythrocytes, parasite cultures were incubated with ethidium bromide (1 g/mL) for FC or with 4'-6-diamidino-2-phenylindole (1 g/mL) for IFA. As a positive control for surface staining, we used antiserum raised against the FCR3 DBL1 domain that has been previously demonstrated to react to FCR3-CSA PEs (J.D.S., unpublished data). Rabbit anti-DBL5 antiserum preincubated with refolded DBL5 or DBL3 domain (1 and 0.25 g/L serum) was used for IFA as an additional control for specificity of reactivity.
We analyzed DBL5 sequences from a clinical isolate. cDNA from cultured 0711 parasites was prepared as described elsewhere [8] . The DBL5 domain of var2csa was amplified using primers (5'-TTGACAATGCAATAAAAGATTAC-3' [forward] and 5'-CATTAAATCCACACGGACATTTAG-3' [reverse]) to flanking sequences, which are conserved among geographically diverse var2csa alleles. After cloning into pcDNA2.1-TOPO (Invitrogen), 26 DBL5 inserts were sequenced, resulting in 3 distinct sequences: 0711-1 (n ϭ 24), 0711-22 (n ϭ 1), and 0711-31 (n ϭ 1). Multiple sequence alignments, phylogenetic tree construction, and principal component analyses were performed using the ClustalW (version 1.83) program suite (http:// www.ebi.ac.uk/clustalw).
Results and discussion. As demonstrated by ELISA, rabbit antiserum had titers of ϳ1:50,000, and mouse antiserum had titers of ϳ1:128,000 against the corresponding immunizing antigens. Rabbit and mouse antisera to refolded DBL5 domain reacted to homologous VAR2CSA on the surface of 3D7-CSA PEs (figure 1A), whereas antiserum against denatured DBL5-IAM did not (data not shown), suggesting that the epitopes on the native protein are conformational. Rabbit antiserum to DBL6 also reacted to homologous 3D7-CSA PEs ( figure 1A ), but none of the antisera to other domains (DBL1, DBL3, and DBL4) demonstrated reactivity to 3D7-CSA PEs (data not shown). The DBL4 domain of VAR2CSA may be hidden or poorly exposed on the PE surface [7] , and this could explain the poor reactivity of DBL4-specific antiserum to the native protein. The poor reactivity of DBL1-or DBL3-specific antiserum is more likely due to incorrect refolding of the recombinant protein or to the selection of adjuvants that have been shown to promote reactive or nonreactive responses to surface proteins variably [7] . DBL domains in VAR2CSA contain several polymorphic loops, and in other systems [13] denatured protein can elicit antibody responses to flexible loops. We speculated that reduced/alkylated DBL5-IAM protein might elicit antibody to surface-exposed loops in VAR2CSA and to native PE surface protein. Instead, antiserum to DBL5-IAM failed to react to PEs. This may indicate that variable loops in DBL domains are partially constrained in their conformation or that reduced and alkylated protein elicit little if any antibody against these variable loops. The results imply that immunogenic epitopes in the unfolded protein are hidden or cryptic in the native protein and raise the possibility that flexible loops may be shielding functional portions of VAR2CSA from the host immune system. Antiserum to the 3D7 DBL5 domain reacted to heterologous FCR3-CSA PEs (figure 1B), whereas antiserum to 3D7 DBL6 did not. This corresponds to the degree of domain sequence conservation in 3D7 and FCR3 parasites (64% identity in DBL6 vs. 84% identity in DBL5). Sequence variation in both domains is concentrated in the exposed flexible loops. Notably, 1 variable loop in DBL5 (between ␣-helix 5 and ␣-helix 7, defined by homology to crystal structures of related DBL domains [14] ) is completely conserved between the 3D7 and FCR3 variants (figure 2), whereas DBL6 domains of 3D7 and FCR3 demonstrate polymorphisms in all flexible loops (data not shown). Taken together, our results imply that most antibodies elicited by DBL5 and DBL6 immunization recognize polymorphic epitopes in the native protein.
The clinical isolate 0711, which originated from a pregnant Tanzanian woman, adhered to CSA at high levels and to CD36 at low levels ( figure 1C, bottom panel) without selection. The reactivity of anti-DBL5 antiserum to 0711 significantly exceeded that of control nonimmune serum (figure 1C) but was relatively low compared with its reactivity to FCR3-CSA parasites (figure 1B). These patterns could be explained by DBL5 sequence variation. Phylogenetic analysis (figure 2) and principal component analysis (data not shown) demonstrate that 3D7 VAR2CSA has greater similarity to FCR3 than to variants transcribed by 0711. This was not expected, because 3D7 groups closely with African isolates, whereas FCR3 is likely to be of Asian origin [15] . Nevertheless, seroreactivity corresponded to sequence similarity, with antiserum to 3D7 variant DBL5 showing greater crossreactivity with FCR3-CSA protein than with 0711 protein.
In general, DBL5 is highly conserved among both laboratory and clinical parasites, and most sequence differences localize to flexible loops in the protein [9, 14] . Despite high overall sequence similarity between VAR2CSA variants, antibody recognition of native protein on PE surfaces varies considerably between parasites and therefore may largely target a few surfaceexposed nonconserved epitopes in the flexible loops. Notably, 3D7 and FCR3 parasites share at least 1 fully conserved DBL5 loop between ␣-helices 5 and 7 (figure 2), whereas none of the DBL5 loops in 0711 shares identity with those in 3D7 or FCR3. This may explain the poor reactivity of antisera to surface protein of 0711 PEs.
VAR2CSA has not previously been detected on the surface of PE in clinical samples, presumably because sequence polymorphisms limit detection. This study is the first to demonstrate VAR2CSA on the surface of clinical isolate PEs, and broadly cross-reactive antisera will be of considerable utility in future . Asterisks indicate conserved residues; colons, conserved substitutions; dots, semiconserved substitutions; bold font, loop conserved between 3D7 and FCR3 variants; underlined residues, ␣-helices identified according to Singh et al. [14] . Bottom, Phylogenetic tree of DBL5 domains from the 3D7, FCR3, and 0711 variants and several other publicly available P. falciparum strains.
studies of clinical samples. In addition, a VAR2CSA vaccine will need to elicit cross-reactive antibody to be widely effective, and the immunogens described here represent the next step in developing such immunogens. Specific features of DBL5 favor it as a vaccine candidate. Other than the DBL4 domain (which may not be accessible to antibody in the native protein [7] ), DBL5 is the most highly conserved VAR2CSA domain. Recombinant DBL5 is well recognized by serum from immune multigravidae [7, 8] , and we show here that anti-DBL5 antibody reacts against native protein from different laboratory strains and a clinical isolate from a pregnant woman. These findings support further evaluation of DBL5 immunogens as candidates for a PM vaccine.
In conclusion, protein expression in E. coli is a robust, inexpensive, and scalable method for vaccine production. Our results suggest that it can be used for the development of a vaccine directed against complex disulfide-rich domains, such as VAR2CSA DBL domains. This is the first study to show that refolded E. coli-expressed VAR2CSA domains can induce an immune response against native VAR2CSA and elicit antibodies that cross-react with different strains, including a clinical isolate from a pregnant woman. An effective PM vaccine will need to elicit antibodies that cross-react with heterologous VAR2CSA from different parasite strains. Further studies are needed to determine the number of domains and variants required to elicit panreactive antibodies against placental PEs and which of these domains can elicit functional antibody to block binding or opsonize the parasites.
